A rational, triple-drug, fixed-dose combination (FDC) antihypertensive therapy that provides synergistic blood pressure control through complementary mechanisms: Angiotensin II Receptor Blockade (ARB), Dual L/N-type Calcium Channel Blockade (CCB), and Thiazide-like Diuretic action. This combination is particularly effective for moderate to severe hypertension, offers renal and cardiac protection, and is associated with a lower incidence of peripheral edema compared to other CCBs.
Adult: One tablet (Telmisartan 40mg + Cilnidipine 10mg + Chlorthalidone 12.5mg) once daily, preferably in the morning.
Note: Swallow whole with a glass of water, with or without food (but consistent timing is advised). Taking it in the morning minimizes nocturia. Do not crush or chew.
This combination exerts a multi-pronged attack on hypertension: 1) Telmisartan selectively blocks the binding of angiotensin II to the AT1 receptor, inhibiting vasoconstriction, aldosterone secretion, and sympathetic outflow. 2) Cilnidipine blocks both L-type (vascular) and N-type (neuronal) voltage-gated calcium channels, causing vasodilation and suppressing norepinephrine release from sympathetic nerve endings. 3) Chlorthalidone inhibits sodium reabsorption in the distal convoluted tubule of the nephron, promoting natriuresis and diuresis, reducing plasma volume and peripheral vascular resistance.
Pregnancy: CONTRANDICATED in 2nd and 3rd trimesters (FDA Category D). Drugs that act directly on the RAAS can cause fetal injury and death, including oligohydramnios, fetal renal dysfunction, skull hypoplasia, and pulmonary hypoplasia. Discontinue as soon as pregnancy is detected.
Driving: Caution advised, especially during initiation and dose adjustment, as dizziness, lightheadedness, or syncope may occur, affecting ability to drive or operate machinery.
| Other Antihypertensives (ACEi, Beta-blockers, Alpha-blockers) | Additive hypotensive effect, risk of severe hypotension. | Major |
| Potassium-sparing diuretics (Spironolactone, Amiloride), Potassium supplements, Salt substitutes | Increased risk of hyperkalemia (due to Telmisartan). | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | Reduced antihypertensive effect; increased risk of renal impairment and hyperkalemia. | Major |
| Lithium | Chlorthalidone reduces renal clearance of lithium, leading to toxicity. | Major |
| Digoxin | Chlorthalidone-induced hypokalemia can potentiate digoxin toxicity. | Moderate |
| CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increase Cilnidipine plasma levels, risk of hypotension and edema. | Moderate |
| CYP3A4 Inducers (Rifampicin, Phenytoin, Carbamazepine) | Decrease Cilnidipine plasma levels, reducing efficacy. | Moderate |
| Corticosteroids | Counteract hypokalemic and antihypertensive effects of Chlorthalidone. | Moderate |
| Allopurinol | Increased risk of hypersensitivity reactions when combined with Chlorthalidone. | Moderate |
| Antidiabetic drugs (Insulin, Sulfonylureas) | Chlorthalidone may worsen glycemic control, requiring dose adjustment. | Moderate |
Same composition (Telmisartan (40mg) + Cilnidipine (10mg) + Chlorthalidone (12.5mg)), different brands: